Biotech Values

[DewDiligence]

AGN:

Latisse sales did not improve much from last quarter…

Actually, Latisse sales did improve by a significant % from 1Q09 to 2Q09 when you adjust for the wholesale channel fill in 1Q09. The absolute numbers are still tiny, of course.

…but guidance for the year was raised.

The increase in 2009 guidance for Latisse (from $30-50M to $60M) is consistent with AGN’s M.O., which is to give very conservative product-specific guidance and subsequently raise it, perhaps several times.

By the way, one analyst proposed that AGN’s “male” version of Latisse for application to the scalp be called Matisse :- )